Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Sep;19(9):1187-93.
doi: 10.1007/BF00965154.

Inhibition by n-3 fatty acids of arachidonic acid metabolism in a primary culture of astroglial cells

Affiliations

Inhibition by n-3 fatty acids of arachidonic acid metabolism in a primary culture of astroglial cells

A Petroni et al. Neurochem Res. 1994 Sep.

Abstract

Docosahexaenoic acid (22:6 n-3) was present in low concentrations in a primary culture of rat brain astroglial cells, when compared to brain cortex. We have thus supplemented these cells with this fatty acid and investigated the effects of its incorporation in cell phospholipids on the conversion of arachidonic acid, 20:4 n-6, through the cyclo and lipoxygenase pathways, after cell stimulation. Docosahexaenoic acid-enriched cells produced less thromboxane B2 and 6-keto-Prostaglandin F1 alpha and markedly less 12-hydroxyeicosatetraenoic acid than unsupplemented cells, after stimulation with the Ca(2+)-ionophore A23187. The production of 15-hydroxyeicosatetraenoic acid from arachidonic acid was slightly increased in docosahexaenoic acid-supplemented cells. We have also supplemented these cells with eicosapentaenoic acid (20:5 n-3) and, in addition to accumulation of this fatty acid in cell phospholipids, we found elevation of 22:5 n-3 and some increment of 22:6, confirming that glial cells are able to convert eicosapentaenoic acid to the long chain, more unsaturated derivatives. In conclusion, n-3 fatty acids, when supplemented to glial cells, appear to modulate the arachidonic acid cascade and to be converted through the elongation and desaturation pathways.

PubMed Disclaimer

References

    1. Brain Res. 1987 Sep 1;419(1-2):364-8 - PubMed
    1. Neurobiology. 1972;2(3):97-105 - PubMed
    1. Biochem Pharmacol. 1988 Apr 1;37(7):1275-80 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1988 Dec;338(6):704-7 - PubMed
    1. J Lipid Res. 1983 Dec;24(12):1595-604 - PubMed

LinkOut - more resources